透云生物(01332.HK)中期持续经营业务收入约3660万港元 同比减少约20.8%

Core Viewpoint - The company,透云生物, reported a significant improvement in profit despite a decline in revenue, indicating a potential recovery in financial performance driven by fair value gains on financial assets [1] Financial Performance - For the six months ending June 30, 2025, the company recorded revenue of approximately HKD 36.6 million, a decrease of about 20.8% compared to the same period last year [1] - The overall gross profit margin for the company was 37.0%, down from 41.4% for the six months ending June 30, 2024 [1] - The company achieved a profit of HKD 28.1 million for the period, a substantial improvement of HKD 76.9 million compared to a loss of HKD 48.8 million for the same period in 2024 [1]